Jan 09, 2024 / 10:15PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat this afternoon with Eli Lilly. Lilly has obviously had a tremendous few years here and really looking forward to our discussion with Dave Ricks, the company's Chairman and CEO.
So Dave, Happy New Year. Thanks for joining us. I know you're going to make some opening remarks, and then we'll jump into Q&A from there.
David A. Ricks - Eli Lilly and Company - Chairman, CEO & President
Super. Thanks, Chris. Good to be back. Okay. Great. Thank you all for being here, and thanks for that introduction, Chris. I thought I'd give a little bit of a slide presentation because it's been a while since I did that, 2018. So I'll use that as my reference point backwards. That's also the year that Chris Schott put a buy on Lilly. Turned out to work pretty well.
So really, the theme of this is like how can we drive continued R&D and innovation excellence at
Eli Lilly and Co at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers